Spineway reported its H1 2025 financial results, showing a net loss of €1.4 million, a significant improvement from the €3.4 million loss in the same period in 2024. The company confirmed its full-year 2025 growth target and highlighted a solid cash position of €4 million as of June 30, 2025.

Operating performance improved in the first half of 2025, with a 1-point increase in gross margin to 69% and a 3% reduction in net operating costs. Personnel expenses were reduced by €311 thousand (-12%), and general operating costs decreased by €146 thousand (-7%).

Spineway’s financial loss narrowed by €2 million to €1.4 million in the first half of 2025, compared to €3.4 million in the same period in 2024. The company also noted a solid cash position of €4 million as of June 30, 2025, with net cash totaling €2.5 million after deducting financial debt.

The company confirmed its full-year 2025 revenue growth target and highlighted its efforts to drive growth in international markets through training programs for surgeons and the commercial launch of the ESP product range in Indonesia. Spineway enters the second half of 2025 with confidence and a strong financial foundation.

Read more at GlobeNewswire: Spineway : H1 2025 results